Krystal Biotech, Inc.
One of the first gene-therapy companies to reach patients, it makes VYJUVEK, a gel applied to open wounds that treats dystrophic epidermolysis bullosa (DEB), a rare disease where skin blisters like butterfly wings. Founded in 2016 by husband-and-wife team Krish and Suma Krishnan, who self-funded its start, the company named itself "Krystal" for the clarity and precision it wanted in gene therapy.
Granted 205.5K · Bought 175.0K · Sold 1.00M
Granted 193.1K · Bought 150.0K · Sold 1.02M
Granted 37.9K · Bought 200.0K · Sold 385.6K
Granted 18.9K · Sold 59.0K
Granted 132.7K · Sold 90.5K
Granted 20.0K · Sold 20.0K
Granted 6.3K · Bought 2.8K
Bought 9.0K
Granted 12.5K · Sold 12.5K
Granted 1.0K · Sold 1.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Krishnan Krish SPresident and CEO, Director, 10% owner · 249 transactions | — | 6.06M | 205.5K | 175.0K | 1.00M |
| Krishnan SumaPresident, R&D, Director, 10% owner · 257 transactions | — | 6.05M | 193.1K | 150.0K | 1.02M |
| Janney DanielDirector · 42 transactions | — | 164.1K | 37.9K | 200.0K | 385.6K |
| Rossi Dino ADirector · 6 transactions | — | 89.5K | 18.9K | — | 59.0K |
| Romano KathrynChief Accounting Officer · 96 transactions | — | 22.4K | 132.7K | — | 90.5K |
| Gangolli Julian SDirector · 4 transactions | — | 20.0Kas of May 2024 | 20.0K | — | 20.0K |
| Riley Antony AChief Financial Officer · 2 transactions | — | 9.1Kas of Nov 2019 | 6.3K | 2.8K | — |
| Norby R DouglasDirector · 1 transaction | — | 9.0Kas of May 2018 | — | 9.0K | — |
| Orth Andrew C.Chief Commercial Officer · 4 transactions | — | 7.3Kas of Jun 2023 | 12.5K | — | 12.5K |
| Thomas John CharlesEVP, General Counsel · 3 transactions | — | 1.0K | 1.0K | — | 1.6K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -2.05M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.